Results 281 to 290 of about 13,113,839 (405)

A CLINICAL TRIAL OF A MIXTURE OF LEVORPHANOL AND LEVALLORPHAN AS AN ORAL ANALGESIC

, 1964
JOHN W. DUNDEE
openalex   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Hydrophobic and Hydrophilic IOLs in Patients with Uveitis - A Randomised Clinical Trial. [PDF]

Clin Ophthalmol
Pålsson S, Schuborg C, Sterner B, Andersson Grönlund M, Zetterberg M.   +4 more
europepmc   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial.

JAMA Netw Open
Dong Z, Luo P, Sun S, Ni Z, He Y, Huang X, Liu Z, Wu Z, Zhang X, Liao Y, Zhao J, Lin H, Zhang X, Fu R, Ding G, Xu Y, Wang L, Xiao Y, Shi S, Zuo X, Li Z, Qiao L, Wang R, Li W, Wan J, Li Y, Guan T, Deng X, Wu X, Zheng H, Chen J, He L, Yamaguchi S, Wang H, Cai GY, Zhang L, Chen X.   +36 more
europepmc   +1 more source

Commentary on "Potassium Permanganate in Treatment of Diabetic Foot Ulcer: A Randomized Clinical Trial". [PDF]

Health Sci Rep
Babazadeh A, Barary M, Mohseni Afshar Z, Ebrahimpour S.   +3 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Patient-Selection of a Clinical Trial Primary Outcome: The ENHANCE-AF Outcomes Survey. [PDF]

PLoS One
Stafford RS, Rice EN, Shah R, Hills MT, Nunes JC, DeSutter K, Lin A, Lhamo K, Lin B, Lu Y, Wang PJ.   +10 more
europepmc   +1 more source

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213 [PDF]

, 1975
Geoffrey Falkson, J. J. Van Dyk, Errol B. van Eden, Alma M. van der Merwe, J. A. Van Den Bergh, H. C. Falkson   +5 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source